Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-05-25 Earnings Release
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia to present promising nadunolimab efficacy in non-small cell lung cancer at ASCO 2023, including two complete responses
Earnings Release Classification · 97% confidence The document is a press release from Cantargia announcing that they will present updated interim efficacy data for their drug nadunolimab at the ASCO 2023 meeting. It details clinical results (ORR, PFS, OS) and includes comparative tables. The text concludes with a statement: "*This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation...*" and provides links to the presentation abstract and the full poster/document. Since this is an announcement about upcoming presentation of data, and it is not the full Annual Report (10-K), a comprehensive Interim Report (IR), or a formal Earnings Release (ER) focusing on financial performance, it best fits the category for general regulatory announcements or press releases that don't fit elsewhere. Given the context of a company announcing clinical trial updates and upcoming presentation details, it is most appropriately classified as a general Regulatory Filing (RNS), which serves as a broad category for such corporate disclosures under EU regulations (like MAR, mentioned in the text). It is not a Report Publication Announcement (RPA) because it is announcing the presentation of data, not just the publication of a pre-existing financial report. FY 2023
2023-05-25 English
Annual General Meeting in Cantargia AB (publ)
AGM Information Classification · 98% confidence The document explicitly states it contains the resolutions passed at the 'Annual General Meeting in Cantargia AB (publ)' held on May 23, 2023. It details decisions regarding dividends, board discharge, board composition, remuneration, auditor re-election, and approval of various schemes and amendments. This content directly corresponds to the materials presented or finalized following an AGM. Although it mentions an attachment, the core content provided is the summary of the AGM resolutions, making 'AGM-R' the most appropriate classification over a general 'RPA' or 'RNS'.
2023-05-23 English
Årsstämma i Cantargia AB (publ)
AGM Information Classification · 99% confidence The document text is titled 'Årsstämma i Cantargia AB (publ)' which translates to 'Annual General Meeting in Cantargia AB (publ)'. The content details the resolutions passed at this meeting held on May 23, 2023, including decisions on dividends, board remuneration, election of directors and auditors, and changes to the articles of association. These are the typical outcomes and materials associated with an Annual General Meeting (AGM). Therefore, the classification should be AGM-R (AGM Information). The document is not a proxy statement (PSI) as it reports the results, nor is it a general earnings release (ER) or annual report (10-K).
2023-05-23 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) for the period 'Januari – Mars 2023'. It contains detailed financial highlights (net sales, operating profit, earnings per share), management commentary on business performance, and updates on clinical trials. It is a comprehensive quarterly financial report, not an announcement of a report or a simple earnings release, as it provides substantive financial data and analysis. Q1 2023
2023-05-23 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT' and covers the period 'January - March 2023'. It contains detailed financial highlights (Net sales, Operating loss, Loss after tax, etc.), a Chief Executive's review, and a comprehensive overview of the company's clinical trial progress and project portfolio. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2023
2023-05-23 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage by Avanza Bank Holding AB for its pension subsidiary, specifically noting the 'Reason for major shareholding notification' and providing exact share quantities and resulting percentages (5.01989% directly held, 5.66277% total). This structure perfectly matches the definition of a Major Shareholding Notification, which reports when ownership crosses specific thresholds. The relevant code is MRQ.
2023-05-22 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.